Search research articles
Contact Us
Filters
Showing results (201-210 of 246) with videos related to
Page
of 25
Sort By:
Circulation
|
November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
Acta Cardiologica Sinica
|
April 29, 2016
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis
Kang-Ling Wang, Pao-Hsien Chu, Cheng-Han Lee, et al.
JACC. Asia
|
November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Kieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.
Annals of Internal Medicine
|
April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial
Jawad H Butt, Pooja Dewan, Béla Merkely, et al.
Circulation
|
April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
European Heart Journal
|
November 17, 2019
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Peter R Sinnaeve, Gregory G Schwartz, Daniel M Wojdyla, et al.
JACC. Asia
|
February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
Xiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Journal of the American Heart Association
|
June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance
Mingming Yang, Toru Kondo, Pooja Dewan, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 246) with videos related to
Sort By:
Page
of 25
Circulation
|
November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
Acta Cardiologica Sinica
|
April 29, 2016
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis
Kang-Ling Wang, Pao-Hsien Chu, Cheng-Han Lee, et al.
JACC. Asia
|
November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Kieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.
Annals of Internal Medicine
|
April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial
Jawad H Butt, Pooja Dewan, Béla Merkely, et al.
Circulation
|
April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
European Heart Journal
|
November 17, 2019
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Peter R Sinnaeve, Gregory G Schwartz, Daniel M Wojdyla, et al.
JACC. Asia
|
February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
Xiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Journal of the American Heart Association
|
June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance
Mingming Yang, Toru Kondo, Pooja Dewan, et al.
Page
of 25